Abstract
The association between diabetes and risk of prostate cancer has been investigated widely. However, study results remain inconsistent and contradictory. Using a meta-analytic approach, the present study explore the relationship incorporating more recent studies and provide more powerful evidence without the limitations of any individual study. Relevant studies were identified by searching Pubmed and the Cochrane Central Register of Controlled Trials through May 18, 2012. The strength of the relationship between diabetes mellitus and risk of prostate cancer was assessed using relative risk (RR). Either a fixed effects or random effects model was used to calculate the pooled RRs. Stratification analyses and sensitivity analyses were conducted, and publication bias was assessed by Egger’s test and Begg’s test. Twelve case–control studies involving 9,767 cases and 19,790 controls, and 25 cohort studies involving 118,825 cases were included. The person-years of follow-up ranged from 29,963 to 6,264,890 among included cohort studies. Diabetes was not significantly associated with incidence of prostate cancer in our analysis of case–control studies only (RR = 0.846, 95 % CI [0.710, 1.009]) or that of cohort studies only (RR = 0.925, 95 % CI [0.811, 1.054]). However, through subgroup analyses, statistically significant associations between diabetes and prostate cancer were found when considering population-based studies only (RR = 0.719, 95 % CI [0.637, 0.812]), cohort studies conducted in the United States (RR = 0.789, 95 % CI [0.727, 0.857]), and studies with follow-up of more than 5 years. Compared to risk of prostate cancer among people without diabetes, diabetic patients using insulin treatment experienced reduced incidence of prostate cancer in both case–control and cohort studies. The results suggest that diabetes mellitus is associated with decreased incidence of prostate cancer, specifically in the population of the United States. In addition, the time since onset of diabetes was positively associated with decreasing incidence of prostate cancer. The present conclusions should be considered carefully, however, and confirmed with further studies.
References
Deng L, Gui Z, Zhao L, Wang J, Shen L (2012) Diabetes mellitus and the incidence of colorectal cancer: an updated systematic review and meta-analysis. Dig Dis Sci 57(6):1576–1585
Wang P, Kang D, Cao W, Wang Y, Liu Z (2012) Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis. Diabetes Metab Res Rev 28(2):109–122
Ben Q, Xu M, Ning X et al (2011) Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of cohort studies. Eur J Cancer 47(13):1928–1937
Onishi S, Takemoto M, Ishikawa T et al. (2012) Japanese diabetic patients with Werner syndrome exhibit high incidence of cancer. Acta Diabetol. doi:10.1007/s00592-012-0424-z
Nicolucci A (2010) Epidemiological aspects of neoplasms in diabetes. Acta Diabetol 47(2):87–95
Bonovas S, Filioussi K, Tsantes A (2004) Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia 47(6):1071–1078
Kasper JS, Giovannucci E (2006) A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 15(11):2056–2062
Wallström P, Bjartell A, Gullberg B, Olsson H, Wirfält E (2009) A prospective Swedish study on body size, body composition, diabetes, and prostate cancer risk. Br J Cancer 100(11):1799–1805
Martin RM, Vatten L, Gunnell D, Romundstad P, Nilsen TI (2009) Components of the metabolic syndrome and risk of prostate cancer: the HUNT 2 cohort. Norway. Cancer Causes Control 20(7):1181–1192
Lee MY, Lin KD, Hsiao PJ, Shin SJ (2012) The association of diabetes mellitus with liver, colon, lung, and prostate cancer is independent of hypertension, hyperlipidemia, and gout in Taiwanese patients. Metabolism 61(2):242–249
Tseng CH (2011) Diabetes and risk of prostate cancer: a study using the National Health Insurance. Diabetes Care 34(3):616–621
Li Q, Kuriyama S, Kakizaki M et al (2010) History of diabetes mellitus and the risk of prostate cancer: the Ohsaki Cohort Study. Cancer Causes Control 21(7):1025–1032
Chodick G, Heymann AD, Rosenmann L et al (2010) Diabetes and risk of incident cancer: a large population-based cohort study in Israel. Cancer Causes Control 21(6):879–887
Moses KA, Utuama OA, Goodman M, Issa MM (2012) The association of diabetes and positive prostate biopsy in a US veteran population. Prostate Cancer Prostatic Dis 15(1):70–74
Ganesh B, Saoba SL, Sarade MN, Pinjari SV (2011) Risk factors for prostate cancer: an hospital-based case-control study from Mumbai, India. Indian J Urol 27(3):345–350
Pelucchi C, Serraino D, Negri E, Montella M, Dellanoce C, Talamini R, La Vecchia C (2011) The metabolic syndrome and risk of prostate cancer in Italy. Ann Epidemiol 21(11):835–841
Wu C, Moreira DM, Gerber L, Rittmaster RS, Andriole GL, Freedland SJ (2011) Diabetes and prostate cancer risk in the REDUCE trial. Prostate Cancer Prostatic Dis 14(4):326–331
Turner EL, Lane JA, Donovan JL et al (2011) Association of diabetes mellitus with prostate cancer: nested case-control study (Prostate testing for cancer and treatment study). Int J Cancer 128(2):440–446
Baradaran N, Ahmadi H, Salem S et al (2009) The protective effect of diabetes mellitus against prostate cancer: role of sex hormones. Prostate 69(16):1744–1750
Pierce BL, Plymate S, Ostrander EA, Stanford JL (2008) Diabetes mellitus and prostate cancer risk. Prostate 68(10):1126–1132
Johnson JA, Bowker SL, Richardson K, Marra CA (2011) Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias. Diabetologia 54(9):2263–2271
Wallner LP, Morgenstern H, McGree ME et al (2011) The effects of metabolic conditions on prostate cancer incidence over 15 years of follow-up: results from the Olmsted County Study. BJU Int 107(6):929–935
Grundmark B, Garmo H, Loda M, Busch C, Holmberg L, Zethelius B (2010) The metabolic syndrome and the risk of prostate cancer under competing risks of death from other causes. Cancer Epidemiol Biomarkers Prev 19(8):2088–2096
Atchison EA, Gridley G, Carreon JD, Leitzmann MF, McGlynn KA (2011) Risk of cancer in a large cohort of US veterans with diabetes. Int J Cancer 128(3):635–643
Waters KM, Henderson BE, Stram DO, Wan P, Kolonel LN, Haiman CA (2009) Association of diabetes with prostate cancer risk in the multiethnic cohort. Am J Epidemiol 169(8):937–945
Kasper JS, Liu Y, Giovannucci E (2009) Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study. Int J Cancer 124(6):1398–1403
Leitzmann MF, Ahn J, Albanes D et al (2008) Diabetes mellitus and prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Causes Control 19(10):1267–1276
Darbinian JA, Ferrara AM, Van Den Eeden SK, Quesenberry CP Jr, Fireman B, Habel LA (2008) Glycemic status and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 17(3):628–635
Calton BA, Chang SC, Wright ME et al (2007) History of diabetes mellitus and subsequent prostate cancer risk in the NIH-AARP Diet and Health Study. Cancer Causes Control 18(5):493–503
Gong Z, Neuhouser ML, Goodman PJ et al (2006) Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 15(10):1977–1983
Velicer CM, Dublin S, White E (2007) Diabetes and the risk of prostate cancer: the role of diabetes treatment and complications. Prostate Cancer Prostatic Dis 10(1):46–51
Tande AJ, Platz EA, Folsom AR (2006) The metabolic syndrome is associated with reduced risk of prostate cancer. Am J Epidemiol 164(11):1094–1102
Johnson JA, Bowker SL (2011) Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. Diabetologia 54(1):25–31
Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ 330:1304–1305
Hitron A, Adams V, Talbert J, Steinke D (2012) The influence of antidiabetic medications on the development and progression of prostate cancer. Cancer Epidemiol 36(4):e243–e250
Chang CH, Toh S, Lin JW et al (2011) Cancer risk associated with insulin glargine among adult type 2 diabetes patients–a nationwide cohort study. PLoS ONE 6(6):e21368
Ben Sahra I, Laurent K, Giuliano S et al (2010) Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res 70(6):2465–2475
Weinstein D, Simon M, Yehezkel E, Laron Z, Werner H (2009) Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells. Diabetes Metab Res Rev. 25(1):41–49
Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535
Little J, Bradley L, Bray MS et al (2002) Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations. Am J Epidemiol 156:300–310
Crowther M, Lim W, Crowther MA (2010) Systematic review and meta-analysis methodology. Blood 116(17):3140–3146
DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188
Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101
Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634
Tavani A, Gallus S, Bertuzzi M et al (2005) Diabetes mellitus and the risk of prostate cancer in Italy. Eur Urol 47(3):313–317
González-Pérez A, García Rodríguez LA (2005) Prostate cancer risk among men with diabetes mellitus (Spain). Cancer Causes Control 16(9):1055–1058
Coker AL, Sanderson M, Zheng W, Fadden MK (2004) Diabetes mellitus and prostate cancer risk among older men: population-based case-control study. Br J Cancer 90(11):2171–2175
Zhu K, Lee IM, Sesso HD, Buring JE, Levine RS, Gaziano JM (2004) History of diabetes mellitus and risk of prostate cancer in physicians. Am J Epidemiol 159(10):978–982
Tavani A, Gallus S, Bosetti C et al (2002) Diabetes and the risk of prostate cancer. Eur J Cancer Prev 11(2):125–128
Rosenberg DJ, Neugut AI, Ahsan H, Shea S (2002) Diabetes mellitus and the risk of prostate cancer. Cancer Invest 20(2):157–165
Rodriguez C, Patel AV, Mondul AM, Jacobs EJ, Thun MJ, Calle EE (2005) Diabetes and risk of prostate cancer in a prospective cohort of US men. Am J Epidemiol 161(2):147–152
Weiderpass E, Ye W, Vainio H, Kaaks R, Adami HO (2002) Reduced risk of prostate cancer among patients with diabetes mellitus. Int J Cancer 102(3):258–261
Will JC, Vinicor F, Calle EE (1999) Is diabetes mellitus associated with prostate cancer incidence and survival? Epidemiology 10(3):313–318
Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Willett WC (1998) Diabetes mellitus and risk of prostate cancer (United States). Cancer Causes Control 9(1):3–9
Wideroff L, Gridley G, Mellemkjaer L et al (1997) Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 89:1360–1365
Smith GD, Egger M, Shipley MJ, Marmot MG (1992) Post-challenge glucose concentration, impaired glucose tolerance, diabetes, and cancer mortality in men. Am J Epidemiol 136:1110–1114
Coughlin SS, Neaton JD, Sengupta A (1996) Cigarette smoking as a predictor of death from prostate cancer in 348,874 men screened for the multiple risk factor intervention trial. Am J Epidemiol 143:1002–1006
Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ (1996) Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 88(16):1118–1126
Corona G, Monami M, Rastrelli G et al (2011) Type 2 diabetes mellitus and testosterone: a meta-analysis study. Int J Androl 34(6 Pt 1):528–540
Gatenby VK, Kearney MT (2010) The role of IGF-1 resistance in obesity and type 2 diabetes-mellitus-related insulin resistance and vascular disease. Expert Opin Ther Targets 14(12):1333–1342
Cohen P, Peehl DM, Lamson G, Rosenfeld RG (1991) Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. J Clin Endocrinol Metab 73:401–407
Rowlands MA, Gunnell D, Harris R, Vatten LJ, Holly JM, Martin RM (2009) Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis. Int J Cancer 124(10):2416–2429
Hsing AW, Chua S Jr, Gao YT et al (2001) Prostate cancer risk and serum levels of insulin and leptin: a population-based study. J Natl Cancer Inst 93:783–789
Lehrer S, Diamond EJ, Stagger S, Stone NN, Stock RG (2002) Increased serum insulin associated with increased risk of prostate cancer recurrence. Prostate 50:1–3
Perseghin G, Calori G, Lattuada G et al. (2012) Insulin resistance/hyperinsulinemia and cancer mortality: the Cremona study at the 15th year of follow-up. Acta Diabetol. doi:10.1007/s00592-011-0361-2
Wells GA, Shea B, O’Connell D et al. (2012) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm Cited 19 June 2012
Yang X, So WY, Ma RC et al. (2012) Synergistic effects of low LDL cholesterol with other factors for the risk of cancer in type 2 diabetes: the Hong Kong Diabetes Registry. Acta Diabetol. doi:10.1007/s00592-012-0409-y
Acknowledgments
We thank and Lijun Zhang (PhD, Chongqing Medical University, Chongqing, China) for finding the full text of relevant articles.
Conflict of interest
The authors declare that they have no competing interests.
Author information
Authors and Affiliations
Corresponding author
Additional information
Communicated by Massimo Federici.
The author F. Zhang and Y. Yang contributed equally to this study.
Rights and permissions
About this article
Cite this article
Zhang, F., Yang, Y., Skrip, L. et al. Diabetes mellitus and risk of prostate cancer: an updated meta-analysis based on 12 case–control and 25 cohort studies. Acta Diabetol 49 (Suppl 1), 235–246 (2012). https://doi.org/10.1007/s00592-012-0439-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00592-012-0439-5